 Tomoo Iwakuma
Concepts (354)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tumor Suppressor Protein p53 | 32 | 2024 | 41 | 9.230 |
Why?
| | Neoplasms | 15 | 2024 | 128 | 3.950 |
Why?
| | Bone Neoplasms | 10 | 2019 | 23 | 3.330 |
Why?
| | Animals | 52 | 2024 | 729 | 3.120 |
Why?
| | Osteosarcoma | 11 | 2020 | 19 | 3.020 |
Why?
| | Mutation | 13 | 2024 | 212 | 2.450 |
Why?
| | Mice | 39 | 2023 | 348 | 2.330 |
Why?
| | HSP40 Heat-Shock Proteins | 3 | 2021 | 5 | 2.140 |
Why?
| | Carrier Proteins | 7 | 2015 | 35 | 2.090 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 13 | 2024 | 14 | 1.860 |
Why?
| | Humans | 52 | 2024 | 6896 | 1.680 |
Why?
| | Cell Movement | 8 | 2016 | 71 | 1.490 |
Why?
| | Mutant Proteins | 4 | 2021 | 6 | 1.480 |
Why?
| | Signal Transduction | 11 | 2021 | 132 | 1.400 |
Why?
| | Lung Neoplasms | 5 | 2016 | 23 | 1.310 |
Why?
| | Neoplasm Metastasis | 9 | 2021 | 19 | 1.300 |
Why?
| | Cell Line, Tumor | 18 | 2024 | 99 | 1.300 |
Why?
| | Liver Neoplasms | 6 | 2020 | 15 | 1.300 |
Why?
| | Apoptosis | 12 | 2023 | 52 | 1.260 |
Why?
| | Gene Expression Regulation, Neoplastic | 8 | 2019 | 59 | 1.190 |
Why?
| | Membrane Proteins | 3 | 2021 | 54 | 1.170 |
Why?
| | Receptor, Adenosine A3 | 2 | 2017 | 2 | 1.150 |
Why?
| | Actinin | 3 | 2015 | 3 | 1.020 |
Why?
| | Cell Transformation, Neoplastic | 7 | 2021 | 16 | 0.960 |
Why?
| | Carcinogenesis | 3 | 2021 | 9 | 0.900 |
Why?
| | Biomarkers, Tumor | 3 | 2021 | 65 | 0.890 |
Why?
| | RNA, Small Interfering | 6 | 2017 | 22 | 0.800 |
Why?
| | Mevalonic Acid | 2 | 2017 | 2 | 0.750 |
Why?
| | Disease Models, Animal | 7 | 2021 | 71 | 0.750 |
Why?
| | Pancreatic Neoplasms | 5 | 2020 | 13 | 0.730 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2020 | 4 | 0.730 |
Why?
| | Skin Neoplasms | 1 | 2020 | 11 | 0.720 |
Why?
| | Lipid Metabolism | 2 | 2017 | 9 | 0.720 |
Why?
| | MicroRNAs | 1 | 2020 | 27 | 0.710 |
Why?
| | Proto-Oncogene Proteins | 5 | 2011 | 18 | 0.690 |
Why?
| | Sarcoma | 1 | 2019 | 6 | 0.680 |
Why?
| | Soft Tissue Neoplasms | 1 | 2019 | 6 | 0.680 |
Why?
| | Cell Cycle Checkpoints | 2 | 2019 | 4 | 0.670 |
Why?
| | Tumor Suppressor Proteins | 3 | 2020 | 15 | 0.620 |
Why?
| | Mutation, Missense | 1 | 2018 | 28 | 0.620 |
Why?
| | NF-kappa B | 2 | 2016 | 14 | 0.590 |
Why?
| | Cell Death | 1 | 2016 | 4 | 0.570 |
Why?
| | Nuclear Proteins | 4 | 2010 | 52 | 0.570 |
Why?
| | Membrane Glycoproteins | 1 | 2016 | 14 | 0.560 |
Why?
| | Cell Proliferation | 9 | 2020 | 58 | 0.560 |
Why?
| | Oncogenes | 2 | 2021 | 3 | 0.540 |
Why?
| | Peptide Hydrolases | 2 | 2012 | 2 | 0.530 |
Why?
| | Multiprotein Complexes | 2 | 2012 | 4 | 0.520 |
Why?
| | Injections | 1 | 2015 | 5 | 0.520 |
Why?
| | Femur | 1 | 2015 | 10 | 0.520 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2015 | 4 | 0.520 |
Why?
| | RNA, Messenger | 7 | 2024 | 115 | 0.480 |
Why?
| | Gene Knockdown Techniques | 5 | 2021 | 13 | 0.450 |
Why?
| | Receptor, ErbB-2 | 1 | 2012 | 4 | 0.430 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2012 | 8 | 0.430 |
Why?
| | Disease Progression | 3 | 2021 | 111 | 0.430 |
Why?
| | Genes, p53 | 3 | 2010 | 5 | 0.430 |
Why?
| | Neoplasm Invasiveness | 4 | 2020 | 29 | 0.410 |
Why?
| | Pseudopodia | 1 | 2012 | 6 | 0.410 |
Why?
| | Li-Fraumeni Syndrome | 3 | 2009 | 3 | 0.410 |
Why?
| | Male | 13 | 2023 | 3337 | 0.380 |
Why?
| | Chromosome Segregation | 1 | 2011 | 2 | 0.380 |
Why?
| | Mitosis | 1 | 2011 | 2 | 0.380 |
Why?
| | Antigens, Surface | 1 | 2010 | 2 | 0.360 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2010 | 5 | 0.360 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2020 | 3 | 0.360 |
Why?
| | Mice, Knockout | 8 | 2023 | 59 | 0.350 |
Why?
| | Mice, Nude | 4 | 2017 | 10 | 0.340 |
Why?
| | Female | 13 | 2021 | 3525 | 0.330 |
Why?
| | Proteinase Inhibitory Proteins, Secretory | 2 | 2020 | 2 | 0.330 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2019 | 21 | 0.320 |
Why?
| | Serine | 2 | 2004 | 2 | 0.310 |
Why?
| | Gene Expression | 4 | 2021 | 67 | 0.310 |
Why?
| | Ubiquitination | 4 | 2019 | 7 | 0.290 |
Why?
| | Protein Isoforms | 2 | 2017 | 16 | 0.290 |
Why?
| | Protein Processing, Post-Translational | 3 | 2014 | 6 | 0.270 |
Why?
| | Phosphoric Monoester Hydrolases | 2 | 2023 | 2 | 0.270 |
Why?
| | Gene Silencing | 3 | 2019 | 13 | 0.260 |
Why?
| | Tumor Cells, Cultured | 5 | 2017 | 25 | 0.260 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2019 | 15 | 0.260 |
Why?
| | Multigene Family | 1 | 2005 | 8 | 0.260 |
Why?
| | Genetic Vectors | 3 | 1999 | 9 | 0.260 |
Why?
| | DNA | 3 | 2023 | 41 | 0.250 |
Why?
| | O(6)-Methylguanine-DNA Methyltransferase | 3 | 2023 | 3 | 0.250 |
Why?
| | Down-Regulation | 3 | 2016 | 15 | 0.250 |
Why?
| | Heterografts | 2 | 2021 | 3 | 0.240 |
Why?
| | Ubiquitin-Protein Ligases | 3 | 2011 | 11 | 0.240 |
Why?
| | Asia | 1 | 2024 | 10 | 0.240 |
Why?
| | Proteolysis | 2 | 2021 | 3 | 0.240 |
Why?
| | RNA Interference | 2 | 2016 | 16 | 0.240 |
Why?
| | Kisspeptins | 2 | 2014 | 2 | 0.230 |
Why?
| | Polyphosphates | 1 | 2023 | 1 | 0.230 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2023 | 2 | 0.230 |
Why?
| | Neoplasm Staging | 2 | 2021 | 33 | 0.230 |
Why?
| | Neoplasm Proteins | 2 | 2016 | 31 | 0.230 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 71 | 0.230 |
Why?
| | Glioblastoma | 1 | 2023 | 17 | 0.230 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 39 | 0.220 |
Why?
| | Protein Binding | 3 | 2019 | 31 | 0.220 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2021 | 41 | 0.210 |
Why?
| | Aged | 3 | 2023 | 378 | 0.200 |
Why?
| | cdc42 GTP-Binding Protein | 1 | 2021 | 1 | 0.200 |
Why?
| | rac1 GTP-Binding Protein | 1 | 2021 | 2 | 0.200 |
Why?
| | Unfolded Protein Response | 1 | 2021 | 3 | 0.200 |
Why?
| | Disease Susceptibility | 1 | 2021 | 11 | 0.200 |
Why?
| | Desmosomes | 1 | 2021 | 1 | 0.200 |
Why?
| | Arrhythmogenic Right Ventricular Dysplasia | 1 | 2021 | 3 | 0.190 |
Why?
| | Proteome | 1 | 2021 | 3 | 0.190 |
Why?
| | Adult | 3 | 2017 | 1181 | 0.190 |
Why?
| | DNA Damage | 3 | 2012 | 9 | 0.190 |
Why?
| | Mice, Inbred C57BL | 6 | 2012 | 92 | 0.190 |
Why?
| | Immunity, Innate | 1 | 2021 | 16 | 0.190 |
Why?
| | ATP-Binding Cassette Transporters | 2 | 2011 | 4 | 0.190 |
Why?
| | Aurora Kinase A | 1 | 2020 | 3 | 0.180 |
Why?
| | Middle Aged | 3 | 2019 | 608 | 0.180 |
Why?
| | STAT5 Transcription Factor | 1 | 2020 | 6 | 0.180 |
Why?
| | Pimozide | 1 | 2020 | 4 | 0.180 |
Why?
| | Mice, Transgenic | 6 | 2011 | 35 | 0.180 |
Why?
| | DNA Repair | 2 | 2009 | 3 | 0.170 |
Why?
| | Neoplasms, Experimental | 2 | 2008 | 2 | 0.170 |
Why?
| | Terminal Repeat Sequences | 1 | 1999 | 1 | 0.170 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2019 | 3 | 0.170 |
Why?
| | Lentivirus | 1 | 1999 | 4 | 0.170 |
Why?
| | Blotting, Western | 3 | 2016 | 17 | 0.170 |
Why?
| | Electron Transport Complex III | 1 | 2019 | 1 | 0.170 |
Why?
| | Antineoplastic Agents | 2 | 2018 | 55 | 0.160 |
Why?
| | Phenotype | 4 | 2008 | 257 | 0.160 |
Why?
| | Drug Repositioning | 1 | 2018 | 3 | 0.160 |
Why?
| | Amino Acid Substitution | 1 | 2018 | 12 | 0.160 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2018 | 7 | 0.160 |
Why?
| | Gluconeogenesis | 1 | 2017 | 1 | 0.150 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2017 | 2 | 0.150 |
Why?
| | Liver | 2 | 2017 | 126 | 0.150 |
Why?
| | Doxorubicin | 3 | 2010 | 15 | 0.150 |
Why?
| | Methyltransferases | 1 | 1997 | 9 | 0.150 |
Why?
| | Energy Metabolism | 1 | 2017 | 26 | 0.150 |
Why?
| | DNA, Complementary | 1 | 2017 | 9 | 0.150 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2023 | 26 | 0.150 |
Why?
| | Necrosis | 1 | 2016 | 2 | 0.140 |
Why?
| | Pyroptosis | 1 | 2016 | 4 | 0.140 |
Why?
| | Autophagy | 1 | 2016 | 2 | 0.140 |
Why?
| | Promoter Regions, Genetic | 4 | 2019 | 49 | 0.140 |
Why?
| | Neoplastic Stem Cells | 2 | 2020 | 11 | 0.140 |
Why?
| | Up-Regulation | 2 | 2019 | 25 | 0.140 |
Why?
| | Genome, Human | 1 | 2017 | 86 | 0.140 |
Why?
| | Fibroblasts | 3 | 2004 | 26 | 0.140 |
Why?
| | Lung | 1 | 2016 | 65 | 0.140 |
Why?
| | Imidazoles | 1 | 2016 | 2 | 0.130 |
Why?
| | Genes, Dominant | 1 | 2016 | 5 | 0.130 |
Why?
| | Immunoenzyme Techniques | 1 | 2016 | 9 | 0.130 |
Why?
| | Cell Adhesion | 1 | 2016 | 9 | 0.130 |
Why?
| | Piperazines | 1 | 2016 | 3 | 0.130 |
Why?
| | Alleles | 2 | 2016 | 214 | 0.130 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 41 | 0.130 |
Why?
| | Genome-Wide Association Study | 1 | 2016 | 190 | 0.130 |
Why?
| | Tissue Fixation | 1 | 2015 | 2 | 0.130 |
Why?
| | Transplantation, Heterologous | 1 | 2015 | 6 | 0.130 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2015 | 4 | 0.130 |
Why?
| | Neoplasm Transplantation | 1 | 2015 | 8 | 0.130 |
Why?
| | HIV-1 | 3 | 1999 | 26 | 0.120 |
Why?
| | Ultraviolet Rays | 2 | 2004 | 5 | 0.120 |
Why?
| | Furin | 1 | 2014 | 1 | 0.120 |
Why?
| | Breast Neoplasms | 2 | 2011 | 38 | 0.120 |
Why?
| | Mitochondria | 1 | 2013 | 11 | 0.120 |
Why?
| | Stomach Neoplasms | 2 | 2011 | 7 | 0.110 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2010 | 7 | 0.110 |
Why?
| | DNA Repair Enzymes | 2 | 2023 | 2 | 0.100 |
Why?
| | Young Adult | 1 | 2015 | 647 | 0.100 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 7 | 0.100 |
Why?
| | Actins | 1 | 2012 | 5 | 0.100 |
Why?
| | Cell Nucleus | 1 | 2012 | 7 | 0.100 |
Why?
| | Mice, SCID | 1 | 2012 | 13 | 0.100 |
Why?
| | Thymocytes | 1 | 2012 | 1 | 0.100 |
Why?
| | Receptors, Interleukin-7 | 1 | 2012 | 2 | 0.100 |
Why?
| | Telomere | 1 | 2012 | 3 | 0.100 |
Why?
| | Models, Biological | 2 | 2019 | 65 | 0.100 |
Why?
| | Blotting, Southern | 2 | 2011 | 2 | 0.100 |
Why?
| | Protein Multimerization | 1 | 2011 | 3 | 0.100 |
Why?
| | Embryonic Development | 1 | 2011 | 13 | 0.100 |
Why?
| | Cell Cycle | 3 | 2007 | 18 | 0.100 |
Why?
| | Interleukin-17 | 1 | 2011 | 1 | 0.100 |
Why?
| | Autoimmunity | 1 | 2011 | 4 | 0.100 |
Why?
| | STAT3 Transcription Factor | 1 | 2011 | 7 | 0.100 |
Why?
| | Metaphase | 1 | 2011 | 1 | 0.100 |
Why?
| | Kinetochores | 1 | 2011 | 1 | 0.100 |
Why?
| | Mad2 Proteins | 1 | 2011 | 1 | 0.100 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2011 | 51 | 0.100 |
Why?
| | Aneuploidy | 1 | 2011 | 4 | 0.100 |
Why?
| | Repressor Proteins | 1 | 2011 | 12 | 0.090 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2011 | 3 | 0.090 |
Why?
| | Cell Separation | 1 | 2011 | 7 | 0.090 |
Why?
| | Calcium-Binding Proteins | 1 | 2011 | 10 | 0.090 |
Why?
| | Cell Cycle Proteins | 1 | 2011 | 18 | 0.090 |
Why?
| | Rats | 4 | 2023 | 106 | 0.090 |
Why?
| | Cells, Cultured | 5 | 2010 | 84 | 0.090 |
Why?
| | Prostatic Neoplasms | 1 | 2011 | 34 | 0.090 |
Why?
| | Receptors, CXCR4 | 1 | 2010 | 5 | 0.090 |
Why?
| | Genes, myc | 1 | 2010 | 1 | 0.090 |
Why?
| | Lymphoma, B-Cell | 1 | 2010 | 1 | 0.090 |
Why?
| | B-Lymphocytes | 1 | 2010 | 24 | 0.090 |
Why?
| | Transcription Factors | 2 | 2024 | 52 | 0.090 |
Why?
| | DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2009 | 1 | 0.080 |
Why?
| | Transcription, Genetic | 2 | 2008 | 44 | 0.080 |
Why?
| | Genes, p16 | 1 | 2008 | 1 | 0.080 |
Why?
| | Adolescent | 1 | 2015 | 2197 | 0.080 |
Why?
| | Cell Survival | 2 | 2018 | 20 | 0.080 |
Why?
| | DNA-Binding Proteins | 3 | 2012 | 39 | 0.080 |
Why?
| | High-Throughput Screening Assays | 2 | 2018 | 4 | 0.080 |
Why?
| | Protein Structure, Tertiary | 1 | 2007 | 14 | 0.070 |
Why?
| | Gene Expression Regulation | 2 | 2004 | 101 | 0.070 |
Why?
| | Pregnancy | 1 | 2007 | 216 | 0.070 |
Why?
| | Glucose | 2 | 2017 | 22 | 0.070 |
Why?
| | Child | 1 | 2015 | 3364 | 0.070 |
Why?
| | Survival Analysis | 2 | 2019 | 50 | 0.060 |
Why?
| | Cell Line | 2 | 2017 | 81 | 0.060 |
Why?
| | Fetal Death | 1 | 2004 | 3 | 0.060 |
Why?
| | Point Mutation | 1 | 2004 | 7 | 0.060 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2004 | 19 | 0.060 |
Why?
| | Deoxyguanosine | 1 | 2023 | 1 | 0.060 |
Why?
| | Nucleosides | 1 | 2023 | 1 | 0.060 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2023 | 1 | 0.060 |
Why?
| | Caspases | 1 | 2023 | 2 | 0.060 |
Why?
| | Enteroendocrine Cells | 1 | 2023 | 1 | 0.060 |
Why?
| | Hepatocyte Nuclear Factor 3-alpha | 1 | 2023 | 1 | 0.060 |
Why?
| | Rats, Wistar | 1 | 2023 | 2 | 0.060 |
Why?
| | Nucleotides | 1 | 2023 | 2 | 0.060 |
Why?
| | Deoxyguanine Nucleotides | 1 | 2023 | 2 | 0.050 |
Why?
| | S Phase | 1 | 2023 | 3 | 0.050 |
Why?
| | Mutagenesis | 2 | 1999 | 5 | 0.050 |
Why?
| | Trans-Activators | 2 | 2004 | 14 | 0.050 |
Why?
| | Survival Rate | 2 | 2017 | 83 | 0.050 |
Why?
| | Polymerase Chain Reaction | 2 | 1999 | 84 | 0.050 |
Why?
| | Nucleotidyltransferases | 1 | 2021 | 1 | 0.050 |
Why?
| | Cytosol | 1 | 2021 | 14 | 0.050 |
Why?
| | G1 Phase Cell Cycle Checkpoints | 1 | 2020 | 1 | 0.040 |
Why?
| | Small Ubiquitin-Related Modifier Proteins | 1 | 1999 | 1 | 0.040 |
Why?
| | RNA Helicases | 1 | 1999 | 2 | 0.040 |
Why?
| | Virus Integration | 1 | 1999 | 1 | 0.040 |
Why?
| | Cytomegalovirus | 1 | 1999 | 2 | 0.040 |
Why?
| | Immediate-Early Proteins | 1 | 1999 | 2 | 0.040 |
Why?
| | Proviruses | 1 | 1999 | 2 | 0.040 |
Why?
| | Transduction, Genetic | 1 | 1999 | 3 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2019 | 7 | 0.040 |
Why?
| | Plasmids | 1 | 1999 | 5 | 0.040 |
Why?
| | Transfection | 1 | 1999 | 22 | 0.040 |
Why?
| | Cattle | 1 | 1999 | 24 | 0.040 |
Why?
| | Human Growth Hormone | 1 | 1999 | 15 | 0.040 |
Why?
| | DNA, Viral | 1 | 1999 | 13 | 0.040 |
Why?
| | Enhancer Elements, Genetic | 1 | 1999 | 19 | 0.040 |
Why?
| | RNA, Viral | 1 | 1999 | 13 | 0.040 |
Why?
| | RNA Splicing | 1 | 1999 | 14 | 0.040 |
Why?
| | Genetic Therapy | 1 | 1999 | 7 | 0.040 |
Why?
| | Indans | 1 | 1999 | 1 | 0.040 |
Why?
| | Thromboxane A2 | 1 | 1999 | 1 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2019 | 48 | 0.040 |
Why?
| | DNA Methylation | 1 | 2019 | 115 | 0.040 |
Why?
| | Phosphorylation | 2 | 2011 | 22 | 0.040 |
Why?
| | Drug Synergism | 1 | 2018 | 7 | 0.040 |
Why?
| | Small Molecule Libraries | 1 | 2018 | 5 | 0.040 |
Why?
| | Dogs | 1 | 2018 | 17 | 0.040 |
Why?
| | Alkylation | 1 | 1998 | 1 | 0.040 |
Why?
| | Methylnitrosourea | 1 | 1998 | 1 | 0.040 |
Why?
| | Mutagens | 1 | 1998 | 1 | 0.040 |
Why?
| | Trimethylsilyl Compounds | 1 | 1998 | 1 | 0.040 |
Why?
| | Gene Targeting | 1 | 1998 | 5 | 0.040 |
Why?
| | Genes, Tumor Suppressor | 2 | 2010 | 4 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 94 | 0.040 |
Why?
| | Imidazoline Receptors | 1 | 2017 | 1 | 0.040 |
Why?
| | Mice, Mutant Strains | 1 | 2017 | 7 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2017 | 9 | 0.040 |
Why?
| | Dimethylnitrosamine | 1 | 1997 | 1 | 0.040 |
Why?
| | Nanoparticles | 1 | 2017 | 1 | 0.040 |
Why?
| | DNA Primers | 2 | 2011 | 30 | 0.040 |
Why?
| | Sex Factors | 1 | 1997 | 68 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2017 | 19 | 0.040 |
Why?
| | DNA, Antisense | 1 | 1997 | 1 | 0.040 |
Why?
| | Neuroectodermal Tumors, Primitive | 1 | 1997 | 1 | 0.040 |
Why?
| | Ribonucleoproteins | 1 | 1997 | 2 | 0.040 |
Why?
| | Sarcoma, Ewing | 1 | 1997 | 7 | 0.040 |
Why?
| | Aged, 80 and over | 1 | 2017 | 151 | 0.040 |
Why?
| | Tumor Burden | 1 | 2016 | 3 | 0.030 |
Why?
| | Prognosis | 1 | 2017 | 211 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2017 | 304 | 0.030 |
Why?
| | Glycolysis | 1 | 2013 | 4 | 0.030 |
Why?
| | Lactic Acid | 1 | 2013 | 3 | 0.030 |
Why?
| | Extracellular Space | 1 | 2013 | 5 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2013 | 19 | 0.030 |
Why?
| | Telomere-Binding Proteins | 1 | 2012 | 2 | 0.030 |
Why?
| | Interleukin-7 | 1 | 2012 | 2 | 0.030 |
Why?
| | Chromosomal Instability | 1 | 2012 | 2 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2012 | 59 | 0.020 |
Why?
| | Cesium Radioisotopes | 1 | 2011 | 1 | 0.020 |
Why?
| | Th1 Cells | 1 | 2011 | 1 | 0.020 |
Why?
| | Mice, Congenic | 1 | 2011 | 2 | 0.020 |
Why?
| | Lymphoid Tissue | 1 | 2011 | 3 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2011 | 11 | 0.020 |
Why?
| | Th17 Cells | 1 | 2011 | 5 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2011 | 12 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2011 | 32 | 0.020 |
Why?
| | Thyroid Gland | 1 | 2011 | 3 | 0.020 |
Why?
| | Cytokines | 1 | 2011 | 48 | 0.020 |
Why?
| | Plicamycin | 1 | 2010 | 1 | 0.020 |
Why?
| | Sp1 Transcription Factor | 1 | 2010 | 1 | 0.020 |
Why?
| | Cell Growth Processes | 1 | 2010 | 2 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 410 | 0.020 |
Why?
| | HCT116 Cells | 1 | 2009 | 2 | 0.020 |
Why?
| | NIH 3T3 Cells | 1 | 2009 | 5 | 0.020 |
Why?
| | Mammals | 1 | 2009 | 4 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2010 | 231 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2010 | 348 | 0.020 |
Why?
| | DNA Replication | 1 | 2004 | 3 | 0.020 |
Why?
| | Phosphoproteins | 1 | 2004 | 14 | 0.020 |
Why?
| | Gamma Rays | 1 | 2004 | 1 | 0.020 |
Why?
| | Papilloma | 1 | 2004 | 1 | 0.020 |
Why?
| | Neoplasms, Squamous Cell | 1 | 2004 | 1 | 0.020 |
Why?
| | Thymus Gland | 1 | 2004 | 2 | 0.020 |
Why?
| | Transcriptional Activation | 1 | 2004 | 9 | 0.020 |
Why?
| | Carcinoma | 1 | 2004 | 7 | 0.020 |
Why?
| | Skin | 1 | 2004 | 15 | 0.020 |
Why?
| | Stem Cells | 1 | 2004 | 29 | 0.020 |
Why?
| | Clone Cells | 1 | 2001 | 2 | 0.010 |
Why?
| | Chimera | 1 | 2001 | 4 | 0.010 |
Why?
| | Restriction Mapping | 1 | 2001 | 6 | 0.010 |
Why?
| | Crosses, Genetic | 1 | 2001 | 6 | 0.010 |
Why?
| | Recombination, Genetic | 1 | 2001 | 5 | 0.010 |
Why?
| | Blastocyst | 1 | 2001 | 4 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 2001 | 9 | 0.010 |
Why?
| | Exons | 1 | 2001 | 34 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1999 | 1 | 0.010 |
Why?
| | RNA, Transfer | 1 | 1999 | 1 | 0.010 |
Why?
| | Protein Inhibitors of Activated STAT | 1 | 1999 | 1 | 0.010 |
Why?
| | RNA | 1 | 1999 | 14 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1999 | 48 | 0.010 |
Why?
| | Gene Products, gag | 1 | 1999 | 1 | 0.010 |
Why?
| | Gene Products, env | 1 | 1999 | 1 | 0.010 |
Why?
| | 5' Untranslated Regions | 1 | 1999 | 2 | 0.010 |
Why?
| | Cytoplasm | 1 | 1999 | 7 | 0.010 |
Why?
| | Binding Sites | 1 | 1999 | 26 | 0.010 |
Why?
| | Protein Engineering | 1 | 1999 | 3 | 0.010 |
Why?
| | HeLa Cells | 1 | 1999 | 17 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 1999 | 50 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1999 | 71 | 0.010 |
Why?
| | Rabbits | 1 | 1999 | 5 | 0.010 |
Why?
| | Muscle Contraction | 1 | 1999 | 3 | 0.010 |
Why?
| | Base Sequence | 1 | 1999 | 81 | 0.010 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 1999 | 5 | 0.010 |
Why?
| | Aorta | 1 | 1999 | 8 | 0.010 |
Why?
| | Heterogeneous-Nuclear Ribonucleoproteins | 1 | 1997 | 1 | 0.010 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 1997 | 1 | 0.010 |
Why?
| | Thionucleotides | 1 | 1997 | 2 | 0.010 |
Why?
| | RNA, Neoplasm | 1 | 1997 | 4 | 0.010 |
Why?
| | RNA-Binding Protein EWS | 1 | 1997 | 2 | 0.010 |
Why?
| | Translocation, Genetic | 1 | 1997 | 4 | 0.010 |
Why?
| | Oncogene Proteins, Fusion | 1 | 1997 | 8 | 0.010 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|